ÂÜÀòÂÒÂ×

Benjamin F. Cravatt is a Professor and the Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease, especially as pertains to the nervous system and cancer. Professor Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from the Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. He is the co-founder and scientific advisor at Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the AACR Award for Outstanding Achievement in Chemistry in Cancer Research, and memberships in the National Academy of Sciences and American Academy of Arts and Sciences.